HRES-1285-119
Referred to the House Committee on Energy and Commerce.
Sponsored by Diana DeGette (D-CO)
What it does
This is a simple resolution expressing the House's opinion (a "sense of the House") that FDA decisions about mifepristone should be based on peer-reviewed scientific evidence rather than political considerations, and that access to medication abortion via telemedicine, mail, and pharmacy dispensing should be preserved. It does not change any law, regulation, or FDA policy, and it does not carry the force of law.
Who benefits
No group gains or loses any legal right or benefit, since the resolution has no binding effect; symbolically it aligns with the interests of abortion-rights advocacy groups, reproductive health providers, and patients who currently rely on telehealth-prescribed mifepristone, and it may be cited in future FDA or judicial proceedings as an expression of congressional sentiment.
Who is hurt
No group faces a direct legal or financial effect, since the resolution is non-binding; symbolically it runs counter to the positions of anti-abortion advocacy organizations and lawmakers who favor tighter mifepristone restrictions, who may view it as inaccurately characterizing the safety debate.
Supporters argue
Supporters argue that mifepristone has a 25-year safety record backed by hundreds of peer-reviewed studies and endorsements from major medical organizations including the AMA and ACOG, and that FDA drug regulation should rest on scientific evidence rather than political pressure. They contend that reaffirming this principle is important given ongoing lawsuits seeking to restrict mifepristone despite what they describe as the absence of new safety concerns since the FDA's 2023 REMS modification.
Opponents argue
Opponents argue that the resolution presents a one-sided characterization of a medically and legally contested issue, asserting mifepristone's safety and the illegitimacy of legal challenges without acknowledging arguments raised in ongoing litigation about post-market safety data. They contend that non-binding resolutions like this substitute political messaging for the FDA's own scientific and regulatory process, and that Congress should not use its voice to prejudge matters properly left to agency review and the courts.
Constitutional context
As a simple resolution, this measure expresses opinion only and creates no legal obligation, so it does not itself raise a constitutional question; however, it touches on the same framework governing FDA drug approval, the Federal Food, Drug, and Cosmetic Act, and post-Dobbs state authority over abortion regulation, since mifepristone litigation continues to test the boundaries between FDA authority and state abortion law under the Supremacy Clause.
Checks and balances
This resolution exercises no binding authority over the executive branch; it is a communicative act by the House expressing its view to the FDA and public, with no enforcement mechanism, leaving actual regulatory authority with the FDA and judicial oversight with the courts.
Historical precedent
The House and Senate have periodically passed non-binding resolutions on abortion-related topics, but this specific mifepristone-focused resolution has no directly analogous prior enactment.